Neurona Therapeutics vs Cradle
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neurona Therapeutics develops interneuron cell therapies derived from human iPSCs to repair dysregulated neural circuits; lead program NRTX-1001 is in Phase 1/2 trials for drug-resistant focal epilepsy;
About
Neurona Therapeutics is a clinical-stage biotherapeutics company founded in 2013 and headquartered in San Francisco, California, that develops regenerative neural cell therapies for chronic neurological disorders. The company generates specific neuronal and glial cell types from human induced pluripotent stem cells (iPSCs) for transplantation into the nervous system, with the goal of repairing dysfunctional neural circuits that underlie conditions such as epilepsy, chronic pain, and other neurological diseases.
AI protein design platform combining language models with lab automation; active learning cycles for enzyme, antibody, and therapeutic protein engineering optimization.
About
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, activity, and manufacturability. Founded in 2021 and headquartered in Amsterdam with teams in San Francisco, Cradle raised approximately $24 million and targets biopharmaceutical, agricultural, and industrial biotechnology companies that need to engineer proteins with specific functional properties.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.